Artiva Biotherapeutics, Inc. - Common Stock (ARTV) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2024 to Q3 2025

Type / Class
Equity / Common Stock
Symbol
ARTV on Nasdaq
Shares outstanding
24,286,350
Price per share
$4.18
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
18,152,764
Total reported value
$52,098,905
% of total 13F portfolios
0%
Share change
-472,367
Value change
-$149,494
Number of holders
39
Price from insider filings
$4.18
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Artiva Biotherapeutics, Inc. - Common Stock (ARTV) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
venBio Global Strategic Fund III, L.P. 4.9% $2,206,114 1,198,975 venBio Global Strategic Fund III, L.P. 31 Mar 2025
BlackRock, Inc. 2% -62% $995,740 -$1,557,557 485,727 -61% BlackRock, Inc. 30 Jun 2025

As of 30 Sep 2025, 39 institutional investors reported holding 18,152,764 shares of Artiva Biotherapeutics, Inc. - Common Stock (ARTV). This represents 75% of the company’s total 24,286,350 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Artiva Biotherapeutics, Inc. - Common Stock (ARTV) together control 74% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 41% 9,853,302 0% 0.35% $28,278,977
5AM Venture Management, LLC 9.7% 2,353,304 0% 2.5% $6,753,982
VR ADVISER, LLC 6.6% 1,609,569 0% 0.26% $4,619,463
venBio Partners LLC 4.7% 1,148,975 0% 1.9% $3,297,558
CITADEL ADVISORS LLC 3.3% 798,397 +419% 0% $2,291,399
FRANKLIN RESOURCES INC 2.1% 520,327 0% 0% $1,493,338
BlackRock, Inc. 1.2% 294,422 -39% 0% $844,992
MILLENNIUM MANAGEMENT LLC 1.1% 262,160 -20% 0% $752,399
WELLINGTON MANAGEMENT GROUP LLP 0.8% 194,108 0% 0% $557,090
VANGUARD GROUP INC 0.66% 159,118 -32% 0% $456,669
BNP PARIBAS FINANCIAL MARKETS 0.49% 118,547 0% 0% $340,230
GEODE CAPITAL MANAGEMENT, LLC 0.46% 110,896 -30% 0% $318,510
CITIGROUP INC 0.43% 105,573 +2860% 0% $302,995
Alyeska Investment Group, L.P. 0.41% 100,000 0% 0% $287,000
RENAISSANCE TECHNOLOGIES LLC 0.33% 79,147 0% $227,152
STATE STREET CORP 0.25% 59,824 -4.9% 0% $171,695
GOLDMAN SACHS GROUP INC 0.2% 49,777 -58% 0% $142,860
XTX Topco Ltd 0.2% 47,973 0.01% $137,683
MORGAN STANLEY 0.18% 42,829 -7.4% 0% $122,919
LANDSCAPE CAPITAL MANAGEMENT, L.L.C. 0.16% 39,133 0.01% $112,311
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.14% 35,000 0% 0% $100,450
HRT FINANCIAL LP 0.11% 26,953 -65% 0% $77,000
Qube Research & Technologies Ltd 0.11% 25,552 -34% 0% $73,334
UBS Group AG 0.09% 21,143 +534% 0% $60,680
TWO SIGMA INVESTMENTS, LP 0.08% 20,364 -4.7% 0% $58,445

Institutional Holders of Artiva Biotherapeutics, Inc. - Common Stock (ARTV) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 18,152,764 $52,098,905 -$149,494 $2.87 39
2025 Q2 18,507,398 $27,946,001 -$5,466,427 $1.51 47
2025 Q1 20,919,533 $62,758,590 -$3,180,577 $3.00 52
2024 Q4 21,161,524 $213,250,346 +$4,529,241 $10.08 57
2024 Q3 20,699,707 $318,929,124 +$305,945,387 $15.45 48